Literature DB >> 11350868

Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

D Ramsay1, N Bevan, S Rees, G Milligan.   

Abstract

The wild-type beta2-adrenoceptor and a constitutively active mutant of this receptor were C-terminally tagged with luciferase from the sea pansy Renilla reniformis. C-terminal addition of Renilla luciferase did not substantially alter the levels of expression of either form of the receptor, the elevated constitutive activity of the mutant beta2-adrenoceptor nor the capacity of isoprenaline to elevate cyclic AMP levels in intact cells expressing these constructs. Treatment of cells expressing constitutively active mutant beta2-adrenoceptor-Renilla luciferase with antagonist/inverse agonist ligands resulted in upregulation of levels of this polypeptide which could be monitored by the elevated luciferase activity. The pEC50 for ligand-induced luciferase upregulation and ligand affinity to bind the receptor were highly correlated. Similar upregulation could be observed following sustained treatment with agonist ligands. These effects were only observed at a constitutively active mutant of the beta2-adrenoceptor. Co-expression of the wild-type beta2-adrenoceptor C-terminally tagged with the luciferase from Photinus pyralis did not result in ligand-induced upregulation of the levels of activity of this luciferase. Co-expression of the constitutively active mutant beta2-adrenoceptor-Renilla luciferase and an equivalent mutant of the alpha1b-adrenoceptor C-terminally tagged with green fluorescent protein allowed pharmacological selectivity of adrenoceptor antagonists to be demonstrated. This approach offers a sensitive and convenient means, which is amenable to high throughput analysis, to monitor ligand binding to a constitutively active mutant receptor. As no prior knowledge of receptor ligands is required this approach may be suitable to identify ligands at orphan G protein-coupled receptors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350868      PMCID: PMC1572784          DOI: 10.1038/sj.bjp.0704077

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment.

Authors:  J A Javitch; D Fu; G Liapakis; J Chen
Journal:  J Biol Chem       Date:  1997-07-25       Impact factor: 5.157

2.  Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells.

Authors:  M Merkouris; I Mullaney; Z Georgoussi; G Milligan
Journal:  J Neurochem       Date:  1997-11       Impact factor: 5.372

3.  Internal trafficking and surface mobility of a functionally intact beta2-adrenergic receptor-green fluorescent protein conjugate.

Authors:  L S Barak; S S Ferguson; J Zhang; C Martenson; T Meyer; M G Caron
Journal:  Mol Pharmacol       Date:  1997-02       Impact factor: 4.436

Review 4.  Agonist-independent regulation of constitutively active G-protein-coupled receptors.

Authors:  R Leurs; M J Smit; A E Alewijnse; H Timmerman
Journal:  Trends Biochem Sci       Date:  1998-11       Impact factor: 13.807

Review 5.  Inverse agonism and the regulation of receptor number.

Authors:  G Milligan; R A Bond
Journal:  Trends Pharmacol Sci       Date:  1997-12       Impact factor: 14.819

Review 6.  Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation.

Authors:  A Scheer; S Cotecchia
Journal:  J Recept Signal Transduct Res       Date:  1997 Jan-May       Impact factor: 2.092

7.  Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists.

Authors:  T W Lee; S Cotecchia; G Milligan
Journal:  Biochem J       Date:  1997-08-01       Impact factor: 3.857

8.  Synergism of constitutive activity in alpha 1-adrenergic receptor activation.

Authors:  J Hwa; R Gaivin; J E Porter; D M Perez
Journal:  Biochemistry       Date:  1997-01-21       Impact factor: 3.162

9.  Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged beta2-adrenergic receptor.

Authors:  L Kallal; A W Gagnon; R B Penn; J L Benovic
Journal:  J Biol Chem       Date:  1998-01-02       Impact factor: 5.157

10.  Agonists induce conformational changes in transmembrane domains III and VI of the beta2 adrenoceptor.

Authors:  U Gether; S Lin; P Ghanouni; J A Ballesteros; H Weinstein; B K Kobilka
Journal:  EMBO J       Date:  1997-11-17       Impact factor: 11.598

View more
  5 in total

1.  Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences.

Authors:  Douglas Ramsay; Elaine Kellett; Mary McVey; Stephen Rees; Graeme Milligan
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

2.  Non-allosteric enzyme switches possess larger effector-induced changes in thermodynamic stability than their non-switch analogs.

Authors:  Jay H Choi; Angela San; Marc Ostermeier
Journal:  Protein Sci       Date:  2013-03-08       Impact factor: 6.725

3.  Regulated and constitutive activation of specific signalling pathways by the human S1P5 receptor.

Authors:  Anke Niedernberg; Andree Blaukat; Torsten Schöneberg; Evi Kostenis
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

4.  A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes.

Authors:  Martin C Michel; Martina B Michel-Reher; Peter Hein
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

5.  A key mammalian cholesterol synthesis enzyme, squalene monooxygenase, is allosterically stabilized by its substrate.

Authors:  Hiromasa Yoshioka; Hudson W Coates; Ngee Kiat Chua; Yuichi Hashimoto; Andrew J Brown; Kenji Ohgane
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-13       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.